StockNews.AI
KROS
StockNews.AI
213 days

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

1. Pomerantz LLP investigates Keros for potential securities fraud. 2. Keros halted two treatment arms of the TROPOS trial due to safety issues. 3. Keros stock declined over 73% after trial dosing halt announcement. 4. Another halt in the TROPOS trial caused a 16.51% further stock drop. 5. Keros faces scrutiny from investors and possible legal action.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Significant stock price drops linked to safety concerns in trials suggest ongoing negative sentiment.

How important is it?

Legal investigations and dramatic stock price falls indicate serious implications for Keros' future.

Why Short Term?

Immediate investor reaction likely affects Keros price, potentially stabilizing with positive news later.

Related Companies

KROS
Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company")(NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Keros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On December 12, 2024, Keros issued a press release "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (‘PAH'), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial."On this news, Keros's stock price fell $50.22 per share, or 73.15%, to close at $18.43 per share on December 12, 2024.Then, on January 15, 2025, Keros issued a press release "announc[ing] that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (‘PAH'), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events." Keros further stated that "[t]he Company has notified investigators and certain regulatory authorities, including the FDA, about this decision, and is in the process of notifying other relevant regulatory authorities."On this news, Keros's stock price fell $2.06 per share, or 16.51%, to close at $10.42 per share on January 15, 2025.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLP

Related News